1. Stent design aspectsPart A – Overview Dr. Amir KraitzerThe contents of materials available on this presentation are reserved. Content may not be reproduced,published,…

Slide 1AGIR 2 Presenter Disclosure Information Eric Bonnefoy The following relationships exist related to this presentation: Research grantsMerck & Co, Iroko LabImportant…

Slide 1VCT vs HD CCTA Exam 92% Dose Reduction James P Earls MD Fairfax Radiological Consultants, Fairfax VA Inova Fairfax Hospital, Falls Church VA Slide 2 History 53 yr…

Slide 1The SELECT-ACS Trial Effects of the P-selectin antagonist inclacumab on myocardial damage after PCI for NSTEMI Effects of the P-selectin antagonist inclacumab on myocardial…

1.Cardiology Symposium James T. DeVries, MD Assistant Professor of Medicine Dartmouth Medical School Dartmouth-Hitchcock Medical Center2. No disclosure or conflicts 3. Outline…

1. NSAID Upper G/I Adverse Effects Minimizing Risks The 1st Palestinian G/I ConferenceMay 20-22-2010 2. NSAIDs– a long history ofanalgesia & toxicity First recorded…

462505 -2553/1 What is ischaemic heart disease? Ischaemic heart disease (IHD) is also called coronary heart disease (CHD) or coronary artery disease (CAD) Ischaemic refers…

PowerPoint Presentation QUESTIONS A 70 year-old non-diabetic otherwise healthy woman admitted for unstable angina has triple vessel disease (70% LAD lesion, 70% circumflex,…

Slide 1 CLINICAL CASES Slide 2 Atrial Fibrillation Case Study #2 ► An 81-year-old white female with a history of chronic, non-valvular AF, a history of a previous ischemic…

Slide 1 CORONARY STENTS yStent DR KRISHNA KUMAR. K MD DM FACC Slide 2 Brachytherapy Cutting Balloon Directional Atherectomy Extraction Atherectomy Laser Atherectomy Perfusion…